GPCR heads into its Q1 2026 earnings print with the options market sending its most bullish signal of the year — even as the stock has shed nearly a quarter of its value over the past month.
The divergence is the sharpest feature of the setup. The put/call ratio dropped to 0.47 on Thursday — more than two standard deviations below its 20-day average of 0.57, and the lowest reading since at least early March. That is unusual call-side skew for a stock that closed at $39.15, down 4% on the day and 24% over the past month. Options traders are leaning aggressively toward upside exposure, not protection, into what is clearly a challenged price environment. The 52-week PCR range of 0.24 to 0.86 puts the current reading in firmly bullish territory relative to recent history.
Short positioning complicates that picture without contradicting it. Short Interest % of Float is running at 9.4% — real but not extreme — and has actually eased marginally over the past week, down around 1.5%. Borrow costs are modest at 0.45% APR, up sharply on the week but from a very low base. Availability remains wide, with the lending pool far from tight by any measure: the 52-week utilization peak of 37% compares with today's reading near 1.6%, meaning the borrow market is essentially untested. Short sellers have a position, but they are not pressing it into the print.
The bull case rests on aleniglipron, Structure's oral GLP-1 candidate, and the approaching FDA End-of-Phase-2 meeting in 2026 — the single most consequential near-term catalyst for the program. An RSI of 30 flags the stock as technically oversold, and the analyst community remains firmly bullish: all 12 covering analysts carry buy-equivalent ratings, with a consensus mean target well above current levels. Canaccord Genuity initiated coverage in late April at Buy with a $101 target, adding a fresh voice to an already constructive chorus. The broader direction of analyst moves since January has been upward — JPMorgan raised its target to $105 and Guggenheim to $140 earlier this year. EPS momentum ranks in the 88th percentile on both 30- and 90-day bases, suggesting estimate revisions have been moving the right way.
The bear case is structural. Structure is pre-revenue in any meaningful sense, burning cash at roughly $279m annually from operations, and competing in a GLP-1 obesity market that now includes the full weight of Eli Lilly and Novo Nordisk. The stock's 41% YTD decline reflects not just market noise but genuine uncertainty about dose selection and the cardiovascular outcomes trial timeline — key questions the FDA End-of-Phase-2 discussion is meant to address. CEO Raymond Stevens sold shares in March, as did the CFO, CTO, CMO, and CSO in a coordinated executive sale at $20.99 — well below current levels, but a reminder that insiders chose to reduce exposure during a recent trough.
The print is therefore less about quarterly financials and more about whether management can frame the Phase 2 data and regulatory path for aleniglipron in a way that closes the gap between a $39 stock and a Street consensus that still implies more than 150% upside from here.
See the live data behind this article on ORTEX.
Open GPCR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
